Management of Severe Acute Respiratory Syndrome

Severe acute respiratory syndrome (SARS) is a highly contagious and predominantly pneumonic illness caused by a novel coronavirus now commonly known as SARS-CoV (1, 2). Since its recognition in February 2003, SARS has spread to 30 countries and has affected over 8,000 people, resulting in almost 700 deaths worldwide (3). In Hong Kong, over 25% of the victims are health care workers, and the fear of this disease has created devastating socioeconomic effects in Hong Kong and worldwide. SARS is a severe and potentially progressive disease, and many patients progress to severe pneumonia and some even die with diffuse alveolar damage (4). Although it is increasingly being recognized that the mode of transmission is predominantly via droplets, it is now suspected that SARS could also be transmitted via fomites and contaminated sewage systems (5). Although the outbreak of SARS has triggered tremendous international research collaboration, which has enabled rapid dissemination of newly found knowledge to combat this frightening condition, there is very little published literature illustrating the experience of clinicians in the management of these patients. As the vast majority of cases occurred in Hong Kong, Singapore, Taiwan, the mainland of China, and Toronto, physicians outside these areas have seldom had the opportunity to manage these patients (4, 6, 7). Although it is commonly agreed that SARS-CoV infection, being a viral illness, does not respond to antibiotic therapy, other treatment modalities are controversial (6, 8–11). In Hong Kong, a combination of corticosteroid and ribavirin, a broad-spectrum antiviral agent, is routinely used. The use of ribavirin has attracted considerable skepticism because it exhibits no in vitro efficacy against SARS-CoV and it is associated with considerable toxicities, including hemolytic anemia (10, 12, 13). Until we have an efficacious vaccine and implementation of effective epidemiologic infection control measures, and in the absence of effective anti-SARS-CoV agents in sight, SARS is likely to remain a major health threat to the world. In this article, we attempt to address the diagnostic and therapeutic experience regarding this new condition, and in doing so we hope our experience will assist clinicians in their encounter with this potentially devastating, poorly understood new disease.

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.